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Abstract
The TGF-β signaling pathway has a significant role in breast cancer initiation and promotion by 
regulating various cellular processes. We evaluated whether genetic variation in eight genes (TGF-
β1, TGF-β2, TGF-βR1, TGF-βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3) is associated with 
breast cancer risk in women from the Breast Cancer Health Disparities Study. A total of 3,524 
cases (1,431 non-Hispanic whites (NHW); 2,093 Hispanics/Native Americans(NA)) and 4,209 
population-based controls (1,599 NHWs; 2,610 Hispanics/NAs) were included in analyses. 
Genotypes for 47 single nucleotide polymorphisms (SNPs) were determined. Additionally, 104 
ancestral informative markers estimated proportion of NA ancestry. Associations with breast 
cancer risk overall, by menopausal status, NA ancestry, and estrogen receptor (ER)/progesterone 
receptor tumor phenotype were evaluated. After adjustment for multiple comparisons, two SNPs 
were significantly associated with breast cancer risk: RUNX3 (rs906296 ORCG/GG = 1.15 95 % CI 
1.04–1.26) and TGF-β1 (rs4803455 ORCA/AA = 0.89 95 % CI 0.81–0.98). RUNX3 (rs906296) and 
TGF-βR2 (rs3773644) were associated with risk in pre-menopausal women (padj = 0.002 and 0.02, 
respectively) and in those with intermediate to high NA ancestry (padj = 0.04 and 0.01, 
respectively). Self-reported race was strongly correlated with NA ancestry (r = 0.86). There was a 
significant interaction between NA ancestry and RUNX1 (rs7279383, padj = 0.04). Four RUNX 
SNPs were associated with increased risk of ER-tumors. Results provide evidence that genetic 
variation in TGF-β and RUNX genes are associated with breast cancer risk. This is the first report 
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of significant associations between genetic variants in TGF-β and RUNX genes and breast cancer 
risk among women of NA ancestry.
Keywords
reast cancer risk; Breast Cancer Health Disparities Study; TGF-β; signaling pathway; Native 
American ancestry; Hispanic; Non-Hispanic white
Introduction
The TGF-β signaling pathway includes several multifunctional cytokines and cell receptors 
that control the activity of particular genes to regulate cellular processes via a SMAD-
mediated signaling cascade [1, 2]. Inhibition of TGF-β signaling occurs in several cancers, 
including breast cancer [3–5]. Genes in this pathway may play a dual role in breast cancer: 
as early tumor suppressors with growth-inhibitory effects, and as late promoters of 
invasiveness and angiogenesis [6]. Genes in the TGF-β-signaling pathway also have been 
linked to expression of estrogen receptors (ER) [7–10]. One study reported that absence of 
the TGF-β response was more likely in ER+ tumors and associated with a poor prognosis 
[10].
There is evidence that Runt-related transcription factors (RUNX) interact with receptor 
regulated SMADs (R-SMADs) and are down-stream effectors of the TGF-β signaling 
pathway [11]. Three RUNX family members play an important tissue-specific role in 
determining the fate of cells during differentiation and growth, and there is increasing 
evidence that loss of function is involved in carcinogenesis [12–14]. In most tumor cells, 
genetic variation in key members of the pathway causes resistance to the growth-inhibitory 
effects of TGF-β signaling [15, 16].
Despite evidence for a role of TGF-β signaling genes in breast cancer, there are sparse data 
for the association of variants in these genes with breast cancer risk. Studies of the 
associations of genetic variants in TGF-β1, TGF-β2, and TGF-β receptors (TGF-βR1, TGF-
βR2, TGF-βR3) with breast cancer risk are inconsistent [5, 17–25], limited by small sample 
sizes [26–31], and data on non-white groups are lacking [29]. Meta-analyses, based 
primarily on non-Hispanic white (NHW) women, have not confirmed associations with the 
most commonly studied single nucleotide polymorphisms (SNPs) [TGF-β1 (rs1800469 and 
rs1982073) and TGF-βR1 (*6A/rs11466445)] with breast cancer risk [5, 18, 23–25], 
although mouse models have demonstrated that these SNPs increase (TGF-β1) and decrease 
(TGF-βR1) gene expression [28, 32–34]. To date, there are few, if any, published studies on 
the association of RUNX genes with breast cancer risk.
We investigated associations of 47 SNPs in eight genes (TGF-β1, TGF-β2, TGF-βR1, TGF-
βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3) with breast cancer risk in the Breast Cancer 
Health Disparities Study (BCHD), a population-based, collaborative study of Hispanic/
Native American (NA) and NHW women living in the United States or Mexico [35]. We 
evaluated whether associations differ by European or NA ancestry, menopausal status, and 
Boone et al. Page 3
Breast Cancer Res Treat. Author manuscript; available in PMC 2014 September 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ER and progesterone receptor (PR) tumor phenotype. Additionally, SNP–SNP interactions 
were assessed.
Methods
Study population
The BCHD study is a consortium of three population-based case–control studies in the 
United States and Mexico: the 4-Corner’s Breast Cancer Study (4-CBCS), the San Francisco 
Bay Area Breast Cancer Study (SFBCS), and the Mexico Breast Cancer Study (MBCS). 
Participants completed an in-person interview and provided a blood or saliva sample for 
DNA extraction [35]. The 4-CBCS participants were between 25 and 79 years of age. 
Eligible cases were diagnosed with a first primary breast cancer (in situ or invasive) between 
10/1999 and 05/2004 in Arizona, Colorado, New Mexico, and Utah. Controls were 
randomly selected and frequency-matched to cases on 5 year age distributions and ethnicity. 
A total of 1,850 cases (1,244 NHW; 606 Hispanic/NA) and 2,057 controls (1,329 NHW; 
728 Hispanic/NA) participated. SFBCS participants were between the ages of 35 and 79 
years and lived in the San Francisco Bay Area. Eligible cases were diagnosed with a first 
primary invasive breast cancer between 04/1995 and 04/2002 (Hispanics) or between 
04/1995 and 04/1999 (NHWs); controls were selected using random-digit dialing and 
frequency-matched to cases on 5 year age distributions and ethnicity. A total of 1,105 cases 
(312 NHW; 793 Hispanic) and 1,318 controls (320 NHW; 998 Hispanic) participated. 
Participants from the MBCS included women between 28 and 74 years of age. Eligible cases 
were diagnosed with a first primary breast cancer (in situ or invasive) between 01/2004 and 
12/2007 across 12 participating hospitals in three main healthcare systems. Controls were 
selected from the participating hospitals’ geostatistic catchment area using a probabilistic 
multistage design and matched to cases on 5 year age distributions, healthcare institute 
membership, and residency. A total of 1,881 women (850 cases, 1,031 controls) 
participated. All participants signed informed written consent prior to participation and the 
Institutional Review Board for Human Subjects at each institution approved the studies.
Data harmonization
Questionnaire data were harmonized across the three studies as previously described [35]. 
Women were classified as pre-menopausal or post-menopausal based on menstrual history 
and menopausal hormone therapy use. Women who reported still having periods were 
classified as pre-menopausal. Women were classified as post-menopausal if they reported 
natural menopause (≥12 months since last period), using hormone replacement therapy, or 
were at or above the 95th percentile of age for race/ethnicity of those reporting natural 
menopause within their study center. Mean ages for natural menopause were 58 and 56 
years for 4-CBCS NHW and Hispanic/NA women, 55 and 56 years for SFBCS NHW and 
Hispanic women, and 54 years for MBCS Hispanic women.
Genetic data
DNA was extracted from either whole blood (n = 7,287) or saliva (n = 634) samples. Whole 
genome amplification (WGA) was conducted on saliva-derived DNA samples prior to 
genotyping. A tag-SNP approach was utilized to capture variation across candidate genes. 
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SNPs were selected using five parameters: (1) linkage disequilibrium (LD) blocks defined 
using a Caucasian LD map and an r2 = 0.8; (2) minor allele frequency (MAF) > 0.1; (3) 
range = ±1500 base pairs (bps) from the initiation codon to the termination codon; (4) 1 
SNP/LD bin; or (5) evidence of functionality. A multiplexed bead array assay based on 
GoldenGate chemistry (Illumina, San Diego, CA) was used for genotyping with a call rate 
of 99.93 % (99.65 % for saliva samples). There were 132 internal blinded replicates (1.6 % 
of the sample set). The duplicate concordance rate was 99.996 % as determined by 193,297 
matching genotypes among sample pairs.
We investigated 47 SNPs in eight genes: TGF-β1 (2 SNPs), TGF-β2 (1 SNP), TGF-βR1 (5 
SNPs), TGF-βR2 (1 SNP), TGF-βR3 (5 SNPs), RUNX1 (8 SNPs), RUNX2 (17 SNPs), and 
RUNX3 (8 SNPs). Supplemental Table 1 provides identification (rs) numbers and 
descriptions of selected SNPs. Minor allele frequencies (MAF) and Hardy-Weinberg 
Equilibrium (HWE) were calculated based on the frequencies of alleles and genotypes in the 
control population. We genotyped 104 Ancestral Informative Markers (AIMs) to 
characterize proportion of NA ancestry. AIMs were selected based on established 
differences in specific alleles between NA and European populations [36, 37].
Tumor characteristics
Statewide cancer registries in Utah, Colorado, Arizona, New Mexico, and California 
provided information on ER and PR tumor phenotype for a subset of 995 (69 %) NHW 
cases and 968 (75 %) Hispanic/NA cases. ER and PR were not available from the MBCS.
Statistical analysis
STRUCTURE 2.0 was utilized to calculate the proportion of genetic admixture based on 
European and NA ancestry [35, 37]. Percent ancestry was categorized, based on the 
distribution of NA ancestry in the control population, allowing sufficient power to assess 
associations of ancestral groups with breast cancer risk (≤28 %, 29–70 %,>70 %) [35]. 
Differences in covariates between self-reported ethnicity and case–control status were tested 
using the Mantel–Haenszel Chi square (χ2). Logistic regression was used to estimate odds 
ratios (OR) for associations of genotypes with breast cancer risk adjusting for age (<40, 40–
49, 50–59, 60–69, 70+), study center (4-CBCS, SFBCS, MBCS) and percent NA ancestry. 
Associations for each SNP were initially assessed assuming a co-dominant mode of 
inheritance. Dominant and/or recessive models were considered when the trend in ORs 
suggested a different mode of inheritance than co-dominant and increased statistical power 
could be gained by collapsing genotypes. Confounding by categories of age, study center, 
NA ancestry, body mass index (BMI), first-degree family history of breast cancer, age at 
menarche, age at menopause, menopausal status, parity, age at first birth, education, oral 
contraceptive use, hormone therapy use, alcohol consumption, and smoking status, and for 
continuous measures of physical activity and NA ancestry. Covariates were considered 
confounders if the univariate p value was ≤0.20 and adjustment produced a change of ≥10 % 
in the effect estimate for the overall association of the genotype with breast cancer risk [38]. 
We did not observe confounding by any factor; nonetheless all models were adjusted for 
age, study center and percentage of NA ancestry.
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Statistical interactions of SNPs with NA ancestry, self-reported ethnicity, and menopausal 
status were assessed using the difference in maximum likelihood estimates for logistic 
regression models with and without an interaction term, using a χ2 test with 2 degrees of 
freedom (2-df) for a co-dominant model, and 1 degree of freedom (1-df) for a dominant or 
recessive model. Risk of each breast cancer subtype (ER/PR tumor phenotype) was 
evaluated using multinomial logistic regression [39, 40]. SNP–SNP interaction models were 
assessed for those SNPs significantly associated with breast cancer risk and considering 
their biological function and potential interactions within the TGF-β signaling pathway.
P values, based on a 1-df Wald χ2 test statistic, were adjusted for multiple comparisons 
taking into account tag-SNPs within each gene using a step-down Bonferroni correction 
method [41]. This method is based on the effective number of independent SNPs determined 
using the SNP spectral decomposition method based on the eigenvalues of the correlation 
matrix among the SNPs for each gene as proposed by Nyholt [42] and modified by Li and Ji 
[43]. This method is conservative, especially when evaluating correlated variables such as 
SNPs within a gene. An adjusted P ≤ 0.05 for main effects and interactions was considered 
statistically significant. All statistical analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC).
Results
The analyses included 7,733 participants (3,524 cases, 4,209 controls) with complete data 
for the SNPs of interest. Approximately 60 % of participants were over 50 years of age, with 
a higher proportion of pre-menopausal women among Hispanic/NA cases (41 vs. 34 %) and 
Hispanic/NA controls (41 vs. 32 %) than NHW (p < 0.0001) (Table 1). Hispanic/NA cases 
tended to less educated (p <0.0001) and have more ER−/PR− tumors than NHW (23 vs. 18 
%) (p = 0.001). Self-reported race/ethnicity was strongly correlated with NA ancestry 
(Cramer’s V, r = 0.86). Nearly all women (99.5 %) from the U.S. who self-reported being 
NHW were in the low NA ancestry group, whereas those who self-reported being 
Hispanic/NA were distributed across the intermediate (75.9 %), low (16.7 %), and high (7.4 
%) NA ancestry groups. The majority of Mexico Hispanics (controls) had high (51.6 %) or 
intermediate (47.3 %) NA ancestry (data not shown).
Of the 47 SNPs evaluated, 10 [RUNX1 (rs7279383 and rs8127225); RUNX2 (rs10948238 
and rs13201287); RUNX3 (rs906296); TGF-β1 (rs4803455); TGF-β2 (rs6604609); TGF-βR1 
(rs6478974); TGF-βR2 (rs3773644); and TGF-βR3 (rs6678564)] were significantly 
associated with breast cancer risk after adjustment for age, study, and NA ancestry (Table 
2). After adjustment for multiple comparisons, a significant increase in breast cancer risk 
was observed for RUNX3 (rs906296 ORCG/GG = 1.15; 95 % CI1.04–1.26; padj = 0.03) and 
an inverse association was observed for TGF-β1 (rs4803455, ORCC/AA = 0.89; 95 % CI 
0.81–0.98; padj = 0.04). TGF-β2 (rs6604609) was significantly associated with reduced risk 
of breast cancer (ORTA/AA = 0.80, 95 % CI 0.71–0.91, p = 0.0002), whereas TGF-βR2 
(rs3773644) was associated with increased risk of breast cancer (ORTT = 1.21, 95 % CI 
1.05–1.40, p = 0.004).
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RUNX3 (rs906296) had a significant interaction with menopausal status before multiple 
comparison adjustment (padj = 0.08), and was significantly associated with increased breast 
cancer risk in pre-menopausal women (ORAA = 1.33; 95 % CI 1.14–1.55 padj = 0.002) 
(Table 3). Although RUNX1 (rs2268288, ORCC = 1.47; 95 % CI 1.03–2.09, padj = 0.26) and 
RUNX3 (rs4478762, ORAA = 1.71; 95 % CI 1.04–2.82, padj = 0.21) were associated with a 
modest increase in post-menopausal breast cancer risk, these were not significant with 
adjustment for multiple comparisons. The SNPs TGF-βR2 (rs3773644, ORTT = 1.32, 95 % 
CI 1.04–1.68, p = 0.02) and TGF-β2 (rs6604609) (ORTA/AA = 0.77, 95 % CI 0.66–0.91, p = 
0.002) were significantly associated with breast cancer risk among pre-menopausal and 
post-menopausal women, respectively (data not shown).
There was significant interaction between NA ancestry and RUNX1 (rs7279383, padj = 
0.04) (Table 4). Women with the highest NA ancestry had a significant increase in risk 
(ORCG/GG = 1.75 95 % CI 1.17–2.63, padj = 0.05), whereas those with low and high NA 
ancestry had nonsignificant reduced risks (ORCG/GG = 0.87 95 % CI 0.76–1.00, padj = 0.41 
and ORCG/GG = 0.82 95 % CI 0.69–0.97, padj = 0.14, respectively). Divergent results were 
also observed by NA ancestry for TGF-β1 (rs1800469); women with intermediate NA 
ancestry had a significant increased risk (ORTT = 1.29, 95 % CI 1.04–1.58, padj = 0.04), 
whereas there was a null association in those with low and high NA ancestry (ORTT = 0.96, 
95 % CI 0.77–1.20, padj = 1.00, and ORTT = 0.92, 95 % CI 0.65–1.30, padj = 0.94, 
respectively). Several SNPs were significantly associated with increased risk in women with 
intermediate NA ancestry, although results were not significantly divergent across NA 
ancestry: RUNX3 (rs906296, ORCG/GG = 1.23, 95 % CI 1.06–1.43, padj = 0.04); and TGF-
βR2 (rs3773644, ORTT = 1.44, 95 % CI 1.11–1.88, p = 0.01) (data not shown). One SNP 
was inversely associated with risk of women with intermediate NA ancestry: TGF-β2 
(rs6604609, ORTA/AA = 0.76, 95 % CI 0.63–0.91, p = 0.003, data not shown). Further 
evaluation of self-reported ethnicity yielded similar results, although no significant 
interactions were observed.
Table 5 shows associations between TGF-β signaling SNPs and breast cancer risk stratified 
by ER/PR tumor phenotype. Only one SNP was significantly different across ER/PR 
phenotypes after adjustment for multiple comparisons (RUNX3, rs7517302, padj = 0.04). 
However, five SNPs were significantly associated with risk within ER/PR phenotype strata 
that remained significant after adjustment for multiple comparisons. RUNX1 (rs7279123) 
was associated with reduced breast cancer risk for ER+/PR− (padj = 0.03). There was 
increased breast cancer risk for ER−/PR+ (RUNX3, rs2236850, padj = 0.03); and increased 
risk for ER−/PR− for RUNX2 rs9463090 (padj = 0.009), RUNX2 rs12333172 (padj = 0.007) 
and RUNX3 rs7517302 (padj = 0.03). There were no associations between SNPs and breast 
cancer risk defined by ER+/PR+ phenotype. We also evaluated interactions between 
individual SNPs and menopausal status within ER phenotypes: no significant interactions 
were observed.
Lastly, SNP–SNP interactions were examined for SNPs with statistically significant main 
effects for breast cancer risk. Only two were statistically significant [RUNX3 (rs7517302 
and rs906296)*TGF-βR1 (rs6748974)]. The combined effect for rs 7517302*rs6748974 (p = 
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0.003) and rs906296*rs6748974 (p = 0.02) resulted in a slight increase in risk (OR = 1.20, 
data not shown).
Discussion
The present analyses suggest that genetic variation in the TGF-β signaling pathway [TGF-
β1, TGF-β2, TGF-βR1, TGF-βR2, TGF-βR3, RUNX1, RUNX2, and RUNX3] influences 
breast cancer risk in Hispanic/NA and NHW women. Four SNPs were associated with breast 
cancer risk [RUNX3 (rs906296); TGF-β1 (rs4803455); TGF-β2 (rs6604609); and TGF-βR2 
(rs3773644)]. Additionally, associations differed by ER/PR tumor phenotype, menopausal 
status, and percentage NA ancestry. In particular, two SNPs, RUNX3 (rs906296) and TGF-
βR2 (rs3773644) were significantly associated with increased risk in pre-menopausal women 
and women of intermediate NA ancestry. Additionally one SNP, TGF-β2 (rs6604609), was 
associated with decreased risk in these groups. This provides further evidence that RUNX3 
interacts with the TGF-β signaling pathway.
Genes from the TGF-β superfamily of cytokines and RUNX family have important roles 
regulating cellular processes and are part of one of the most commonly altered cellular 
signaling pathways in cancer, making them attractive candidates for cancer-related etiology 
[44, 45]. A general biological mechanism for the relationship between TGF-β signaling and 
breast cancer may be a SMAD-mediated pathway which facilitates the transduction of 
signals for target genes involved in cellular processes [1]. In normal mammary cells, TGF-
β1 is reported to have an anti-proliferative effect on epithelial and endothelial mammary 
cells by acting as a tumor suppressor down-regulating cellular growth, differentiation and 
apoptosis [3, 5]. Mouse models also offer evidence that increased levels of TGF-β1 in serum 
strengthen tumor suppressor activity, reducing risk of breast cancer [4]. Immune cells, 
including B-cell, T-cell, and macrophages, secrete TGF-β1, which negatively regulates their 
proliferation, differentiation, and activation by other cytokines. This process makes TGF-β1 
an effective immunosuppressor, and disruption of the signaling pathway is linked to 
autoimmunity, inflammation, and cancer [46].
In most tumor cells, genetic variants can cause resistance to the inhibitory effects of TGF-β 
signaling [15, 16]. Exact mechanisms for resistance remain unknown, although evidence for 
other cancers suggests there may be decreased expression of TGF-β receptors [47, 48], 
oncoproteins such as p53 [49], other tumor suppressors that regulate the pathway such as 
RUNX3 [50], or increased expression of inhibitory SMADs (I-SMAD6 or I-SMAD-7) in the 
extracellular matrix [3]. There is also evidence that when TGF-β1 and TGF-βR1 are 
overexpressed following tumor initiation, they promote angiogenesis via cell migration and 
adhesion factors, resulting in metastasis [3]. RUNX genes have the ability to enhance growth 
regulation by making target cells sensitive to the effects of TGF-β family members. In turn, 
TGF-β genes can activate RUNX genes at the transcription and post-transcriptional levels 
[51, 52]. Most of our findings indicate that genetic variation is associated with increased 
breast cancer risk, suggesting that these genes are no longer acting as tumor suppressors via 
normal signaling.
Boone et al. Page 8
Breast Cancer Res Treat. Author manuscript; available in PMC 2014 September 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Several epidemiological studies have investigated associations between select SNPs in TGF-
β1, TGF-β2, and TGF-β receptors and breast cancer [15, 17, 18, 21, 28–32]. With the 
exception of one [17], most studies are underpowered and results are inconsistent. Only one 
study to date included Hispanic women, Le Marchand et al. [29] reported an inverse 
association for the (CC vs. TT) genotype of TGF-β1 (rs1982073) (ORCC = 0.81 95 % CI 
0.52–1.27) in post-menopausal Hispanic women from the Multiethnic Cohort study; 
however, the number of Hispanic women was small (67 cases, 179 controls) and the analysis 
was underpowered.
Three meta-analyses were conducted for TGF-β1 (rs1800469) and breast cancer risk: no 
association was observed for the recessive model (TT vs. CC/CT) [18, 23, 25]. Although we 
did not find an overall association for the recessive model of rs1800469 also, the co-
dominant model suggested increased risk for women with intermediate NA ancestry. 
Moreover, present study suggests there is moderate LD (r2 = 0.67) between TGF-β1 
(rs1800469) and TGF-β1 (rs4803455) in both Hispanic/NA and NHW women. In our study, 
there was a significant inverse association of TGF-β1 (rs4803455) with breast cancer risk.
The Shanghai Breast Cancer Study [21] conducted a multistage pathway analysis evaluating 
11 genes (341 SNPs) in the TGF-β signaling pathway. Results for two SNPs can be 
compared to those from the present study. Statistically significant results were reported for 
the additive model of TGF-βR1 (rs10733710, OR = 1.11, p = 0.02) and the recessive model 
of TGF-bR3 (rs284185, ORAA = 1.74, p = 0.004), which contrasts with our non-significant 
findings. The nominal p values reported by Ma et al. [21] suggest that their results may not 
be significant if adjusted for multiple comparisons.
Genetic variation among RUNX genes may be important in colorectal cancer [53], but there 
are no epidemiological data for breast cancer. We found several associations between RUNX 
SNPs and breast cancer risk (RUNX3 rs9062696) in women of intermediate to high NA 
ancestry (RUNX3 rs906296 and RUNX1 rs7279383), as well as an interaction with NA 
ancestry (RUNX1 rs7279383). These findings support the hypothesis that genetic variation 
can influence breast cancer differently in Hispanic/NA than NHW women, possibly due to 
unmeasured biological functional variants that influence susceptibility.
TGF-β signaling may alter expression of the estrogen receptor (ERα) and estrogen may 
reciprocally interfere with this signaling [7–9]. ERα activation has been reported to inhibit 
TGF-β1 transcription activity by up to 60 % [54, 55] and RUNX1 has been considered an 
“accessibility factor” for ERα binding sites [9]. RUNX2 decreases ERα mRNA and protein 
levels in breast cancer cells; and RUNX3 may function as a tumor suppressor by 
destabilizing the ERα gene and inhibiting its expression [7, 56]. Our study is the first to 
evaluate associations between TGF-β and RUNX genes with risk of breast cancer stratified 
by ER/PR tumor phenotypes. Four RUNX SNPs were significantly associated with an 
increased risk of ER−/PR− (RUNX2 rs9463090 and rs12333172, RUNX3 rs2236850 and 
rs7517302) and ER−/PR+ (RUNX1 rs7279123) tumors. These novel findings suggest that 
variation in RUNX genes may increase proliferation in ER− breast cells. Although the 
present analysis included 1,963 cases with available data on ER/PR phenotypes, tumor 
phenotype data for cases in MBCS were unavailable, limiting statistical power when 
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evaluating rarer phenotypes (ER−/PR+). Nonetheless, our results support the role of these 
genes in influencing estrogen-related associations with breast cancer.
There are several strengths and limitations for this study. The sample size provided 
sufficient power to evaluate different modes of inheritance and stratified analyses. Genetic 
ancestry, measured by 104 AIMs markers, was used determine biological ancestry in 
addition to self-reported ethnicity, allowing us to focus on the biological basis of 
associations while evaluating lifestyle factors that differ between groups. Because of sparse 
data in the literature for these genes, comparisons to other studies for specific SNPs and the 
interpretation of our findings were guided mostly by in vivo studies. However, we used a 
tag-SNP approach to cover variation across the entire gene, as the selected SNPs are in 
linkage disequilibrium with those not reported. Finally, adjustment for multiple comparisons 
is conservative and may result in false negative associations.
Results from the present study may have implications for the etiology of breast cancer 
phenotypes and disparities between race/ethnic groups for risk. The present study is the first 
to report associations between variants in these genes and ER/PR tumor phenotype, 
menopausal status, and NA ancestry. Our results suggest that variation in these genes may 
explain the previously reported results that Hispanic women have increased risk of pre-
menopausal, ER− breast cancer compared to NHW. Biologic significance of the genes is 
strongly suggested, although specific SNPs that were evaluated may or may not be 
functional. A better understanding of how TGF-β and RUNX genes can switch their role 
from tumor suppressor to promoter in breast carcinogenesis is needed, as well as how these 
genes may influence ER expression. Studies evaluating a larger representation of SNPs in 
this complex signaling pathway will aid in validating our findings.
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